Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

One Year of Adjuvant Trastuzumab Remains Standard of Care

October 3rd 2012

Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.

Dr. Weiner on the T-DM1 Mechanism of Action

October 1st 2012

Dr. Louis Weiner, from Lombardi Comprehensive Cancer Center, on the T-DM1 mechanism of action in HER2-positive breast cancer.

Updated Data Show T-DM1 Improves Overall Survival in HER2-Positive Breast Cancer

October 1st 2012

An updated analysis of the phase III EMILIA trial showed that T-DM1 significantly extended survival in women with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Dr. Garcia on Combination Therapy for Breast Cancer

September 27th 2012

Agustin A. Garcia, MD, from Keck School of Medicine of USC, discusses clinical trials that investigated combination therapy for treating advanced breast cancer.

Subcutaneous Trastuzumab May Offer Benefits Over Standard IV Infusion in Patients With Breast Cancer

September 26th 2012

A new formulation of trastuzumab that is administered subcutaneously appears to be as effective as the approved bodyweight-based intravenous regimen in women with HER2-positive breast cancer.

Dr. Hammond Discusses HER2 Testing Guideline Revisions

September 20th 2012

Pathologist Dr. Elizabeth Hammond, from Intermountain Healthcare, Discusses the Ongoing ASCO/CAP HER2 Testing Guideline Revisions.

Updated BOLERO-2 Data Support Efficacy of Everolimus in Breast Cancer

September 20th 2012

Updated results from the BOLERO-2 trial support the study's earlier findings that mTOR kinase inhibitor everolimus improves survival for postmenopausal patients with breast cancer.

Taking a Novel Look at an Established Agent: Malaria Drug Chloroquine Studied in a Preventive Setting for Early DCIS

September 17th 2012

In this interview, Lance A. Liotta, MD, PhD, discusses the hypothosis that led to the study and the research thus far into chloroquine.

Carrie Stricker on the Efficacy of Survivorship Care Plans

September 17th 2012

Carrie Stricker from the Abramson Cancer Center of the University of Pennsylvania on the Efficacy of Survivorship Care Plans for Posttreatment Breast Cancer Survivors.

Study Supports Role for ALND in Early Breast Cancer

September 14th 2012

Patients with early-stage breast cancer at high risk of residual nodal disease might benefit from axillary lymph node dissection.

Breast Cancer and Its Treatment May Not Cause Long-Term Fatigue

September 11th 2012

New data show that cancer-related fatigue is reported by only "a small minority" of women >6 months after completing adjuvant therapy for breast cancer.

Dr. Howard Burris Discusses the mTOR Inhibitor Everolimus

September 5th 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the mTOR Inhibitor Everolimus for HER2-Negative Breast Cancer.

Dr. Gralow Discusses the Antibody Drug Conjugate T-DM1

September 4th 2012

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, Discusses the Antibody Drug Conjugate T-DM1 for Breast Cancer.

Navigating Breast Cancer Survivorship: Sustaining the Good News

August 30th 2012

Forty years after the declaration of war on cancer, one of the most profound shifts in cancer care today is a new focus on treating those living beyond cancer, as well as those living with cancer.

Dr. Rugo on Antiangiogenic Therapies in Breast Cancer

August 28th 2012

Dr. Hope Rugo, from the UCSF Helen Diller Family Comprehensive Cancer Center, Examines Angiogenesis Inhibition Trials in Advanced Breast Cancer.

FDA Approval Sought for T-DM1

August 27th 2012

Genentech is seeking the FDA's approval to offer T-DM1 for patients with HER2-positive metastatic breast cancer amid updated results from the pivotal EMILIA trial showing significantly improved OS.

Dr. Louis Weiner Discusses the T-DM1 EMILIA Trial

August 27th 2012

Dr. Louis Weiner, from the Lombardi Comprehensive Cancer Center, Discusses the T-DM1 EMILIA Trial for HER2-Positive Breast Cancer.

Radiation Oncologists Often Excluded From Breast Cancer Treatment Decisions

August 23rd 2012

A "substantial minority" of radiation oncologists report that surgeons fail to include them in the breast cancer treatment decision-making process before definitive surgery.

Elaine Mardis on Sensitivity to Aromatase Inhibitors

August 20th 2012

Elaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors

Combination of Anastrozole and Fulvestrant Improves Survival in Metastatic Breast Cancer

August 7th 2012

Researchers found that when anastrozole and fulvestrant are given in combination that patients with metastatic breast cancer experienced longer periods of PFS and OS.